Brainomix Raises £18.8m for AI Stroke and Lung Tools

Why It Matters

The infusion of growth capital underscores rising confidence in AI‑enabled diagnostics, promising faster treatment decisions for stroke and earlier detection of lung fibrosis, which could reshape care pathways and reduce costly delays.

Key Takeaways

• £18.8m Series C raised for AI imaging expansion.
• Focus on US rollout of Brainomix 360 Stroke and E‑Lung.
• FDA‑cleared tools improve stroke triage and lung fibrosis detection.
• Funding led by Parkwalk, Hostplus; Modi Ventures joins.
• Clinical data shows increased thrombectomy rates, reduced transfer delays.

Pulse Analysis

Artificial intelligence is rapidly moving from research labs into bedside decision‑making, and Brainomix’s latest funding round highlights that momentum. By securing £18.8 million, the UK‑based firm can scale two flagship products—Brainomix 360 Stroke and E‑Lung—across the United States and Europe. Both solutions have cleared the U.S. Food and Drug Administration, giving hospitals regulatory confidence to integrate AI‑generated imaging insights directly into emergency and chronic‑care workflows. This regulatory foothold, combined with proven clinical data, positions Brainomix as a front‑runner in the competitive med‑tech AI market.

Brainomix 360 Stroke automates the interpretation of CT and MRI scans, flagging candidates for endovascular thrombectomy and streamlining patient‑transfer decisions. Early studies suggest the tool can raise thrombectomy rates while shaving minutes off triage and transport times, outcomes that directly translate into better neurological recovery and lower hospital costs. Meanwhile, E‑Lung applies proprietary CT‑based biomarkers to quantify fibrosing lung disease progression, offering pulmonologists a quantitative metric for treatment planning and trial enrollment. Together, these platforms address two high‑impact clinical arenas where speed and precision are paramount.

The infusion of capital also signals strong investor belief in the scalability of AI‑driven diagnostics. With backers like Parkwalk Advisors, Hostplus, and new entrant Modi Ventures, Brainomix gains not only financial resources but strategic access to U.S. market channels. As reimbursement frameworks evolve and hospitals seek cost‑effective technology to meet quality metrics, AI tools that demonstrably improve outcomes are likely to see accelerated adoption. In the next few years, Brainomix’s expanded footprint could set new standards for how imaging data informs real‑time therapeutic decisions, reshaping both stroke care pathways and chronic lung disease management.